850892-12-5

Basic information

• Product Name: 3-AMino-5-broMo-4-Methylpyridine
• Synonyms: 3-AMino-5-broMo-4-Methylpyridine;5-broMo-4-Methylpyridin-3-aMine;5-BroMo-4-Methyl-3-aMinopyridine;3-BroMo-4-Methyl-5-aMinopyridine;3-PyridinaMine, 5-broMo-4-Methyl-;5-Bromo-4-methylpyridin-3-ylamine;5-Bromo-4-methy-pyridin-3-ylamine;5-Bromo-4-methyl-3-pyridinamine
• CAS NO: 850892-12-5
• Molecular Formula: C6H7BrN2
• Molecular Weight: 187.03718
• Mol File: 850892-12-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 302 °C at 760 mmHg
• Flash Point: 136.5 °C
• Appearance: /
• Density: 1.593 g/cm³
• Vapor Pressure: 0.00102mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 4.46±0.28(Predicted)
• CAS DataBase Reference: 3-AMino-5-broMo-4-Methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMino-5-broMo-4-Methylpyridine(850892-12-5)
• EPA Substance Registry System: 3-AMino-5-broMo-4-Methylpyridine(850892-12-5)

Safety Data

• Hazardous Substances Data: 850892-12-5(Hazardous Substances Data)

Usage

Description

3-Amino-5-bromo-4-methylpyridine is an organic compound that features a pyridine ring with a bromine atom at the 5th position, a methyl group at the 4th position, and an amino group at the 3rd position. This unique molecular structure endows it with specific chemical properties, making it a valuable intermediate in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
3-Amino-5-bromo-4-methylpyridine is used as a reactant in the preparation of fused nitrogen heterocyclic compounds, which serve as c-Abl kinase inhibitors. These inhibitors are important in the development of drugs targeting various diseases, including cancer, by modulating the activity of c-Abl kinase, a key enzyme involved in cell signaling and regulation.

InChI:InChI=1/C6H7BrN2/c1-4-5(7)2-9-3-6(4)8/h2-3H,8H2,1H3

Upstream product

• 69872-15-7 3-bromo-4-methyl-5-nitropyridine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1

This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)

INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA

The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a hydrate or of a solvate of said base or acid addition salt.

3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

3,5 disubstituted indazole compounds with substituted nitrogen bearing 5-membered heterocycles in the 3-position that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical com